PCSK9 and metabolic syndrome: Recently published results of the GOULD registry on the management of dyslipidemia of ASCVD patients from the United States found ∼10% of patients stated an LDL‐C treatment goal <70 mg/dl, ∼25% in the group treated with a PCSK9‐inhibitor.15